SEIN SEIN THI1, SYLVIE JONCKHEERE1, CHINMAY LAXMESHWAR1, GUSTAVO CORREA1, SARTHAK A RASTOGI1, PARVATI NAIR1, SUYOG S SHETYE1, DINESH P SAWANT1,

Slides:



Advertisements
Similar presentations
Overview of current case and treatment outcome definitions Malgosia Grzemska TB Operations and Coordination Stop TB Department Consultation Impact of WHO-endorsed.
Advertisements

World Health Organization TB Case Definitions
Development of extensive drug resistance in Multi-Drug resistant tuberculosis patients MSF anti-TB programmes in Abkhazia and Uzbekistan Authors: Cathy.
Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.
Dr R.Reesaul Chest Physician Chest Clinic P. D`or Hospital
The Global Plan to Stop TB, (1)
Molecular methods for TB drug resistance testing: what is needed? Experience from Khayelitsha, Cape Town, South Africa Helen Cox, PhD, Burnet Institute.
Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
Outcomes among patients treated for tuberculosis in Limpopo Province, South Africa, Mmakgotso Pilane, Lazarus Kuonza, Eric Maimela.
Tuberculosis Research of INA-RESPOND on Drug-resistant
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
V IRGINIA C OHORT D ATA – 5 YEAR TRENDS AFTER 4 YEARS OF LOCAL COHORT REVIEW Virginia achievement on National TB Indicators for the past 5 years – where.
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Sub module 1 Introduction to HIV care and ART recording and reporting system.
MSF TB Program for Migrants in Tak. Beginnings: MSF TB Programs in Thailand First MSF TB Program in Thailand started in 1985 in Karen camps (Shoklo,
Antiretroviral treatment programme in Thyolo district, Malawi Southern Region. MSF Luxembourg & Thyolo District Health Services - Strategic information.
Diagnostic algorithms of TB case finding and their effect on TB epidemiology in Russian Regions Andrey Maryandyshev, Elena Nikishova Northern State Medical.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
PMDT in Japan June 2016 Takashi Yoshiyama. Proportion of drug resistance, Japan (Ryoken sampling survey) Without treatment
Comprehensive Treatment of Extensively Drug-Resistant Tuberculosis N Engl J Med 2008;359: R2 이 설 라.
Taipei, June Content  Introduction about Vietnam’s Programmatic Management of Drug resistant Tuberculosis (PMDT) and drug resistant tuberculosis.
Priscilla Tsondai, Lynne Wilkinson, Anna Grimsrud, Angelina Trivino,
Drug Resistant Tuberculosis
Treatment for Multi-drug Resistant TB
Community Representative Update
A Way out of Directly Observed Therapy (DOT): Community approaches to Self-Administered Treatment for Rifampicin Resistant Tuberculosis in Khayelitsha,
Management of Tuberculosis: A Surgical Perspective
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
The role of secondary prophylaxis in the management of HIV-VL co-infection: 7-years experience from West Bengal Prof. Rama Prosad Goswami, Department.
TB- HIV Collaborative activities in Romania- may 2006 status
The Patient Triage Concept: Right Diagnosis, Right Treatment
Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital
World Tuberculosis Day 2014
Benjamin Wood Charité Universitätsmedizin Berlin & MSF Genève
Tuberculosis in children in Uzbekistan: Don’t forget drug-resistant TB Junia Cajazeiro, Atadjan Khamraev, Philip Du Cros, Tleubergen Abdrasuliev, Joan.
World Tuberculosis Day 2013
Cecilia Ferreyra – MSF OCBA MSF UK Scientific Day 2017
World Tuberculosis Day 2014
2. Active TB drug-safety monitoring : rationale and mechanisms in the context of TB & MDR-TB treatment Multi-partner training package on active TB drug.
Validating Definitions of Antiretroviral Treatment Failure in Malawi
Comparing shorter with conventional MDR-TB treatment in Uzbekistan 2-month culture conversion rates and treatment outcomes P du Cros1, A Khamraev2, D Lister3,
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Safe and effective bedaquiline treatment of drug-resistant tuberculosis (DR-TB) within the National Bedaquiline Clinical Access Programme in South Africa.
R Nagar 1, Debashish Kundu2, S Chandra2 , A Khanna1
Community Advisory Boards on Repeat:
PAEDIATRIC TUBERCULOSIS MAY STILL BE UNDER DIAGNOSED AND UNDER TREATED
World Tuberculosis Day 2015
The results are in: now what?
Tuberculosis situation in the EU/EEA, 2016
Global programmatic use of bedaquiline and delamanid for drug-resistant TB treatment: progress, challenges, and possible solutions Dr. Vivian Cox Chair,
Models of Care for People with Drug-Resistant TB: Advancements in South Africa Dr. Norbert Ndjeka MD, DHSM (Wits), Dip HIV Man (SA), MMed (Fam Med) (MED)
World Tuberculosis Day 2014
STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) treatment regimens.
World Tuberculosis Day 2016
World Tuberculosis Day 2014
Session 4: Expanded indications for bedaquiline and delamanid
24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.
The results are in! Now what?
Goal Objectives Expected Outcomes
MDR-TB Clinical Trials Landscape Overview: Current and Future Trials
CASE HOLDING FOR PMDT.
Tuberculosis situation in the EU/EEA, 2017
Tuberculosis situation in the EU/EEA, 2017
Sequencing cohorts Open-label Design W8 W12 ≥ 18 years
Tuberculosis situation in the EU/EEA, 2017
Presentation transcript:

SEIN SEIN THI1, SYLVIE JONCKHEERE1, CHINMAY LAXMESHWAR1, GUSTAVO CORREA1, SARTHAK A RASTOGI1, PARVATI NAIR1, SUYOG S SHETYE1, DINESH P SAWANT1, MRINALINI DAS1, HOMA MANSOOR1, PETROS ISAAKIDIS1,2 1 MÉDECINS SANS FRONTIÈRES, MUMBAI, INDIA 2MÉDECINS SANS FRONTIÈRES, OPERATIONAL RESEARCH UNIT, LUXEMBOURG CITY, LUXEMBOURG Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai Sarthak A Rastogi MSF OCB, Mumbai, India

Digesting the Alphabet Soup - DR-TB Easier to Treat Difficult to Treat ??? Drug susceptible TB (DS-TB) Multidrug resistant TB (MDR-TB) Extensive drug resistant TB (XDR-TB) Pre-extensive drug resistant TB (PreXDR-TB) Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Scenario facing DRTB community Challenging Time Exciting Time Difficult to treat drug resistant (DR) patterns are emerging DR TB treatment takes longer (~2 yrs), use of toxic drugs which lacks clinical evidence Fewer Drugs to treat (≥4 required) Dismal cure rates – Globally 48%, HIV/ DR TB co infected – 38% New diagnostic tool – after > 100yrs Renewed interest in TB research Reanimation of age old tools – Surgery After a gap of 50yrs since the last TB drug – we have 2 new drugs Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Background - DR-TB New Drugs Only 2 NEW DRUGS (Bedaquilline - Bdq & Delamanid - Dlm) Bdq & Dlm validated by WHO in 2012 & 2013 to be “conditionally used” and “required monitoring of pharmacovigilance” Bdq is registered only in 9/27 high burdened countries (including India, where a Conditional Access Program is about to start) The price of new drugs is still high – Bdq: 900 USD/course, Dlm: 1700 USD /course New drugs are available to only 2% of patients who need them (AC) Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Setting –MSF Clinic in Mumbai Provides free DR TB and HIV treatment services since 2006 1101 HIV and 253 TB/DR TB beneficiaries Increasing proportion of complex DR TB cases (PreXDR and XDR) Access to Bdq through CU in 2013 – Aug 2015, Dlm since June 2015 Counseling and consent prior to introduction of Bdq and Dlm into back-bone regimen Enrolled DR TB patients (2013-2015) Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Method of study Descriptive Study from routinely recorded and collected medical data Retrospective cohort analysis of 12 patients registered for Bdq and 14 patients for Dlm from Feb 2013 to Dec 2015 (~10% of the global cohort on Dlm) This retrospective analysis met the criteria of the MSF Ethics Review Board for exemption from ethics review ©MSF / Anshul Uniyal Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Characteristic of patients Bedaquiline Group (n=12) Delamanid Group (n=14) Age (yrs) 18-37 17-47 Gender (M:F) 4: 8 4: 10 HIV co-infected 2 Type of DR TB (based on 13 drugs Drug Susceptibility Testing) Pre XDR XDR 3 9 12 Prior exposure to 2nd line anti-TB drugs Yes / No 12 / 0 12 / 2 Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

No of patients by > 2 and < 2 likely working drugs* Results No of patients by > 2 and < 2 likely working drugs* *likely working drugs is arbitrarily defined as drugs either sensitive in DST-results and/ or less-than 3 month-of-exposure Backbone regimens: XDR: Cm, Lfx, Cs, PAS, Cfz, Lzd, Amx/Cluv PreXDR:Cm,Lfx,Cs,Cfz,Lzd,Amx/Cluv, only 1 case with PAS, 1 case with Z XXDR: Cm, Lfx, Cs, Cfz, Lzd, Amx/Cluv Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Outcome 1 died prior to initiation 1 died after Bdq course 2 cured / completed 12 requests for Bdq CU 11 started on treatment 8 doing well on treatment 14 requests for Dlm CU 12 started on treatment 10 doing well on treatment 1 died prior to initiation 1 no effective regimen 2 died on treatment Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Death during treatment Other severe Adverse Events Results – Major SAE Death during treatment Severe Cardio-toxicity (QTc > 500ms) Other severe Adverse Events Bdq (n=11) 1* 2 Dlm (n=12) 2* 2** * 3 deaths = due to evolution of DR TB, no direct relationship with new drugs ** same patients, cardio-toxicity triggered by other side-effects Cardio-toxicity: no need for permanent discontinuation Despite other cardio-toxic drugs in all patients for 1 case - stopped Bdq for 10 days and stopped Cfz until QTc <500 and reintroduced 100 mg, other case – stopped all drugs for 6 days, reintroduced all when Qtc <500 (chronic diarrhoea grade 3- pre-existing condition, PNP – grade 3, moderate depression (on Mitrazepine) Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Discussion Promising outcomes: sustained culture conversion – 16/18 cases Safe ambulatory treatment with adequate monitoring (clinical, lab & ECG) Limitation: Small cohort but one of the 1st ever documented cohort with a high proportion of ≤ 2 likely working drugs (21/26) v/s 4 drugs required for an effective regimen © Sylvie Jonckheere Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Discussion 21 patients with ≤ 2 likely working drugs, 24/26 with prior exposure to 2nd line drugs They need at least two new drugs to establish efficient treatment Too few drugs available Diagnosed too late Access to these new drugs remains difficult Compassionate Use programs and restrictive protocols for Dlm Conditional Access Programs that has cut down access to Bdq QTc: all with recorded QTc (10): experienced increased QTc, Baseline QTc is high (>450, <480) : 66.7% have >450 ms, 4/6 has prior exposure to Cfz and Mfx, 3 case with QTc <450: 1 no exposure to both Cfz and Mfx, 1 exposure to Cfz, 1 to both All patients are on Lfx and Cfz containing regimen when on Bdq avg increase 45 ms (8-98 ms), Max QTC occurred anytime from w1 to W24, most occurrence within 2 mth, two case with grade 3 QTc: suspended Rx and reintroduce when QTc <500 Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Conclusion Use of new TB drugs should be scaled up - not to be preserved as a last chance in case of multiple failures 2 new drugs is not enough in DR TB management: Urgent need for broader access to Bdq + Dlm combination for patients ≤ 2 likely working drugs, Need for large trial data with new regimens, (not just adding new single molecules) Need to tackle on-going transmission in the community Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai

Acknowledgement: MSF team in Mumbai/Delhi and Our Patients who endure their difficult life-journey with DR TB to have access to new drugs! ©MSF / Anshul Uniyal Thank You! Too little, too late; new anti-TB drugs for patients with complex drug-resistant tuberculosis in Mumbai